read about valuation compression in the sector. If Australian biotech stocks face a sell-off due to tariff concerns, fund managers and retail investors might reduce exposure across the sector, impacting companies like NEU even if they are not directly affected.Investor Sentiment & Risk Perception
Biotech/pharma investment often depends on market confidence. If Australian biotech companies face uncertainty due to tariffs, investors might prefer to allocate capital to U.S.-based biotech stocks instead. This could reduce liquidity and investor interest in ASX-listed biotechs, affecting the share price.
i'm super nervous personally, not too sure about others here
read about valuation compression in the sector. If Australian...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |